Q&A

Q&A: API Experts — A Small Molecule's Journey Through API Development

iStock-1210343139-journey-computer-data-development

Developing a small molecule API is often a perilous process for new and emerging pharma companies. The primary goal, whether in early- or late-phase development, is to obtain sufficient material to support your clinical requirements. Yet the regulatory requirements for each phase are different, and they require different skill sets. Here, three of our leading API experts discuss these key challenges, what your company needs to succeed, and how partnering with a capable CDMO can make the biggest difference of all.

Featuring:

  • Stephen Boppart, Director Business Management, API
  • Matt Frizzle, Senior Business Manager, API
  • Iain McGroarty, Senior Business Development Executive, API

VIEW THE Q&A!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Cell & Gene? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: